Camostat (mesylate)

Camostat (mesylate)

• CAS Number: 59721-29-8
• UNSPSC Description: Camostat mesylate (Camostat mesilate) is an orally active, synthetic serine protease inhibitor for chronic pancreatitis. Camostat mesylate, an inhibitor of TMPRSS2, shows antiviral activity against SARS-CoV-2. Camostat mesylate also inhibits the activity of prostasin, trypsin, and matriptase[1][2][3].
• Target Antigen: SARS-CoV; Ser/Thr Protease
• Type: Reference compound
• Related Pathways: Anti-infection;Metabolic Enzyme/Protease
• Field of Research: Infection; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/Camostat-mesylate.html
• Smiles: O=C(OCC(N(C)C)=O)CC1=CC=C(OC(C2=CC=C(NC(N)=N)C=C2)=O)C=C1.CS(=O)(O)=O
• Molecular Weight: 494.52
• References & Citations: [1]Gibo J, et al. Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. Lab Invest. 2005;85(1):75‐89.|[2]Uno Y. Camostat mesilate therapy for COVID-19 [published online ahead of print, 2020 Apr 29]. Intern Emerg Med. 2020;1‐2.|[3]Coote K, et al. Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J Pharmacol Exp Ther. 2009;329(2):764‐774.|[4]Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015;116:76‐84.
• Shipping Conditions: Room Temperature